Robert Spencer, MD
Rheumatology · Englewood, CONPI 1497787352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,300 of the $19,975 with a category attached, or 71.6%. Amgen accounts for 80.3% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $11,015 and has fallen 88.7% since, to $1,241 in 2025.
Across 279 payments — averaging $71.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$16K
- AbbVie$819
- UCB, Inc.$555
- Pfizer$504
- Genentech USA, Inc.$266
- GSK$222
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$14,30072%
- Travel & lodging$790%
- Food & beverage$5,51828%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 78 | $16,031 |
| AbbVie | 35 | $819 |
| UCB, Inc. | 22 | $555 |
| Pfizer | 31 | $504 |
| Genentech USA, Inc. | 22 | $266 |
| GSK | 13 | $222 |
| AstraZeneca(2 entities) | 10 | $208 |
| E.r. Squibb & Sons, L.L.C. | 10 | $183 |
| Lilly USA, LLC | 7 | $135 |
| Boehringer Ingelheim | 4 | $120 |
| Sobi, Inc | 4 | $104 |
| Johnson & Johnson(2 entities) | 5 | $80 |
| Radius Health, Inc. | 3 | $75 |
| Mallinckrodt Hospital Products Inc. | 3 | $72 |
| Novartis | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Hikma Pharmaceuticals USA | 4 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Sebela Pharmaceuticals Inc. | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Mylan Institutional Inc. | 1 | $29 |
| Zimmer Biomet | 1 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Organon | 1 | $18 |
| Celltrion USA Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Sanofi | 1 | $15 |
| Merck | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,975 in reported general payments places this provider in the 85th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 47 | $364,716 |
| Humira(Cf) PenAdalimumab | 19 | $226,934 |
| Humira PenAdalimumab | 12 | $96,466 |
| OrenciaAbatacept | 14 | $80,026 |
| Orencia ClickjectAbatacept | 13 | $75,085 |
| Taltz AutoinjectorIxekizumab | 11 | $72,721 |
| TymlosAbaloparatide | 22 | $57,169 |
| OxycontinOxycodone Hcl | 12 | $14,685 |
| Hydroxychloroquine Sulfate | 374 | $13,176 |
| MethotrexateMethotrexate Sodium | 389 | $10,203 |
| Mycophenolate Mofetil | 50 | $6,827 |
| Prednisone | 517 | $5,118 |
| Gabapentin | 298 | $4,839 |
| Leflunomide | 73 | $4,586 |
| Celecoxib | 129 | $3,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Orencia | $183 | $80,02614 claims |
| Radius Health, Inc.Tymlos | $75 | $57,16922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Englewood
- Ndudi OparaecheEnglewood$36K
- Cherie ReichartEnglewood$11K
- Eric WestermanEnglewood$3K
- Susan ChildressEnglewood$2K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- David TheisColorado Springs$61K
- Rennie McCabeDenver$58K
- Larry MorelandAurora$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.